133 related articles for article (PubMed ID: 8113839)
21. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
[TBL] [Abstract][Full Text] [Related]
22. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH
Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
[TBL] [Abstract][Full Text] [Related]
23. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
25. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
26. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigens.
Tokura Y; Yagi H; Ohshima A; Kurokawa S; Wakita H; Yokote R; Shirahama S; Furukawa F; Takigawa M
Br J Dermatol; 1995 Jul; 133(1):6-12. PubMed ID: 7669641
[TBL] [Abstract][Full Text] [Related]
28. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
[TBL] [Abstract][Full Text] [Related]
29. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome).
Vonderheid EC; Bigler RD; Kotecha A; Boselli CM; Lessin SR; Bernengo MG; Polansky M
J Invest Dermatol; 2001 Sep; 117(3):654-62. PubMed ID: 11564173
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
31. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases.
Klemke CD; Booken N; Weiss C; Nicolay JP; Goerdt S; Felcht M; Géraud C; Kempf W; Assaf C; Ortonne N; Battistella M; Bagot M; Knobler R; Quaglino P; Arheiliger B; Santucci M; Jansen P; Vermeer MH; Willemze R
Br J Dermatol; 2015 Jul; 173(1):93-105. PubMed ID: 25864856
[TBL] [Abstract][Full Text] [Related]
32. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
33. [Interleukin 7 in dermatology. Molecular, immunologic and preclinical aspects].
Möller P; Czarnetzki BM; Schadendorf D
Hautarzt; 1995 Oct; 46(10):676-82. PubMed ID: 7499126
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng WK; Armstrong R; Arai S; Desmarais C; Hoppe R; Kim YH
Sci Transl Med; 2013 Dec; 5(214):214ra171. PubMed ID: 24307695
[TBL] [Abstract][Full Text] [Related]
35. Phorbol myristate acetate-induced expression of high-affinity interleukin 2 receptors and production of interleukin 2 by human acute lymphoblastic leukemia T cells.
Sahraoui Y; Allouche M; Perrakis M; Clemenceau C; Jasmin C; Georgoulias V
Leukemia; 1992 Apr; 6(4):295-303. PubMed ID: 1588792
[TBL] [Abstract][Full Text] [Related]
36. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.
Rook AH; Kubin M; Cassin M; Vonderheid EC; Vowels BR; Wolfe JT; Wolf SF; Singh A; Trinchieri G; Lessin SR
J Immunol; 1995 Feb; 154(3):1491-8. PubMed ID: 7822812
[TBL] [Abstract][Full Text] [Related]
37. The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.
Miyashiro D; Souza BCE; Torrealba MP; Manfrere KCG; Sato MN; Sanches JA
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055124
[TBL] [Abstract][Full Text] [Related]
38. Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation.
McCusker ME; Garifallou M; Bogen SA
J Immunol; 1997 May; 158(10):4984-91. PubMed ID: 9144518
[TBL] [Abstract][Full Text] [Related]
39. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.
Krejsgaard T; Gjerdrum LM; Ralfkiaer E; Lauenborg B; Eriksen KW; Mathiesen AM; Bovin LF; Gniadecki R; Geisler C; Ryder LP; Zhang Q; Wasik MA; Odum N; Woetmann A
Leukemia; 2008 Dec; 22(12):2230-9. PubMed ID: 18769452
[TBL] [Abstract][Full Text] [Related]
40. Sezary syndrome cells unlike normal circulating T lymphocytes fail to migrate following engagement of NT1 receptor.
Magazin M; Poszepczynska-Guigné E; Bagot M; Boumsell L; Pruvost C; Chalon P; Culouscou JM; Ferrara P; Bensussan A
J Invest Dermatol; 2004 Jan; 122(1):111-8. PubMed ID: 14962098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
